Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

Published:2023-06 Issue: Volume:69 Page:441-450
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Sanglier Thibaut^ORCID,Shim Jinjoo,Lamarre Neil,Peña-Murillo Claudia,Antao Vincent,Montemurro Filippo

Funder

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference66 articles.

1. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer;Gabos;J Clin Oncol,2006

2. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era;Olson;Breast,2013

3. Breast cancer brain metastases: the last frontier;Leone;Exp Hematol Oncol,2015

4. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy;Leone;Cancer Med,2015

5. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma;Chamberlain;Neuro Oncol,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study;Cureus;2024-08-16

2. Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System;ESMO Real World Data and Digital Oncology;2024-06

3. ¹⁵³Sm-labeled Fe₃O₄@lapatinib nanoparticles as a potential therapeutic agent for breast cancer: synthesis, quality control, and in vivo evaluation;Journal of Materials Chemistry B;2024

4. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment;Medical Oncology;2023-07-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3